Laboratory of Physiology, University of Ioannina, Ioannina, Greece.
Metab Syndr Relat Disord. 2010 Apr;8(2):173-8. doi: 10.1089/met.2009.0066.
It is known that weight loss is beneficial for obese and overweight subjects with metabolic syndrome. Very few data exist, however, about whether the presence of metabolic syndrome and insulin resistance (IR) influence the response of these subjects to weight-reducing interventions. The current study intends to examine whether the presence of metabolic syndrome and its components could influence weight loss in obese and overweight women during a short-term, dietary-based intervention program.
A total of 107 women aged 49.1 +/- 13.5 years old, with a body mass index (BMI) greater than 25 were studied. The subjects were prescribed a low-fat diet plus weight-reducing drugs when necessary.
After 3 months, the subjects with metabolic syndrome lost more weight than those without (6.62% vs. 4.50%; P < 0.05). There was a positive correlation between the percentage of weight loss and the number of the components of metabolic syndrome present at baseline (Spearman rho = 0.329; P < 0.01). Furthermore, patients in the quartile with the highest homeostasis model assessment index (HOMA-index) lost more weight than the remaining subjects (8.17% +/- 3.34 vs. 5.59% +/- 3.87; P < 0.05). These results were significant, even after adjustment for the medical treatment prescribed.
Obese and overweight patients with metabolic syndrome showed a greater reduction of their body weight, compared to the patients without metabolic syndrome. The components of the metabolic syndrome present at baseline correlated positively with the percentage of the weight loss. Finally, the patients with the highest levels of HOMA-index at baseline lost significantly more weight than those with lower levels of this parameter.
众所周知，减轻体重对患有代谢综合征的肥胖和超重人群有益。然而，关于代谢综合征和胰岛素抵抗（IR）是否会影响这些人群对减肥干预的反应，仅有很少的数据。本研究旨在探讨肥胖和超重女性在短期基于饮食的干预计划中，代谢综合征及其组分的存在是否会影响体重减轻。
共 107 名年龄 49.1±13.5 岁、BMI 大于 25 的女性参与了研究。研究对象被规定服用低脂饮食加减肥药物。
3 个月后，患有代谢综合征的受试者比不患有代谢综合征的受试者体重减轻更多（6.62%比 4.50%；P＜0.05）。体重减轻的百分比与基线时代谢综合征组分的数量呈正相关（Spearman rho=0.329；P＜0.01）。此外，在四分之一位中，稳态模型评估指数（HOMA-index）最高的患者比其余患者体重减轻更多（8.17%±3.34比 5.59%±3.87；P＜0.05）。即使在调整了规定的治疗后，这些结果仍然显著。
与不患有代谢综合征的患者相比，患有代谢综合征的肥胖和超重患者体重减轻更多。基线时代谢综合征的组分与体重减轻的百分比呈正相关。最后，基线时 HOMA-index 水平最高的患者比该参数水平较低的患者体重减轻显著更多。
